Showing results (51-60 of 211) with videos related to

Sort By:
Pageof 22
BMC Cancer|March 27, 2021
Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapyLauren A Marcath, Colin M Finley, Siu Fun Wong, et al.
British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.
Clinical Pharmacology and Therapeutics|December 7, 2023
Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant AllelesJavier Granados, Amy L Pasternak, N Lynn Henry, et al.
JCO Oncology Practice|March 3, 2022
Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine ChemotherapyKyoin Koo, Amy L Pasternak, N Lynn Henry, et al.
Pharmacogenetics and Genomics|September 3, 2025
Association of genetic variation with irinotecan infusion reactions and severe toxicityKelly I Nugent, Lyucheng Huang, Maisa Nazzal, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 12, 2018
Drug interaction screening in SWOG clinical trialsDaniel L Hertz, Rivka Siden, Jessie Modlin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 21, 2020
Comparison of eight screening tools to detect interactions between herbal supplements and oncology agentsFaisal Shakeel, Fang Fang, Kelley M Kidwell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2002
Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolismJames M Rae, Nadia V Soukhova, David A Flockhart, et al.
Breast Cancer Research : BCR|January 30, 2008
The role of single nucleotide polymorphisms in breast cancer metastasisJames M Rae, Todd C Skaar, Susan G Hilsenbeck, et al.
Pageof 22